Printer Friendly

LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN

 LA JOLLA, Calif., April 26 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today that at its annual organizational meeting, completed on April 23, the board of directors reappointed Dr. David H. Katz as president and chief executive officer, Michael H. Lorber as vice president, chief financial officer and secretary, Timothy R. Russell as vice president of business development and appointed Daniel J. Paracka to the previously vacant position of board chairman.
 Mr. Paracka has been a LIDAK director since early 1992. He previously served as chief financial officer of the Rorer Group and Revlon Health Care Group and is currently senior consultant with the Rand Group. Mr. Paracka said, "I am honored to serve as chairman of the board and to have this opportunity to facilitate the work of the directors. My assumption of these organizational duties should enable Dr. Katz to focus more freely on his primary scientific and management responsibilities." At the same meeting the board approved a new employment contract with Dr. Katz, replacing the current agreement, the initial term of which would otherwise have expired in September of this year.
 LIDAK currently has three ongoing Phase II clinical trials underway in the United States and Europe on LIDAKOL(TM), its topical therapy for herpes infections. In addition, the company is conducting the product manufacturing studies needed to submit an IND application to the FDA for LMI, its potential anti-cancer vaccine therapy.
 -0- 4/26/93
 /CONTACT: Michael H. Lorber, vice president and CFO of LIDAK, 619-558-0364; or Fern Lazar or Kate de Santis of Dewe Rogerson, 212-688-6840, for LIDAK/
 (LDAKA)


CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: PER

WB-GK -- NY118 -- 0962 04/26/93 16:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 26, 1993
Words:281
Previous Article:CLARK EQUIPMENT CO. OPERATIONS RETURN TO BLACK
Next Article:WESTINGHOUSE CREDIT PREFERRED STOCKHOLDERS CONSENT TO MERGER
Topics:


Related Articles
LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
LIDAK PHARMACEUTICALS ANNOUNCES RESIGNATIONS
LIDAK PHARMACEUTICALS ISSUES STATEMENT ON RESIGNATION OF DONALD E. MOSLER
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
LIDAK PHARMACEUTICALS APPOINTS NEW VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
LIDAK ANNOUNCES RETURN OF FORMER CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
LIDAK Pharmaceuticals Appoints Susan Yeagley Sullivan As New Chief Financial Officer

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters